Revelation Biosciences, Inc. (NASDAQ:REVB) | WebDisclosure

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Headlines Articles Press releases Revelation Biosciences, Inc.

Home
Companies
Revelation Biosciences, Inc.

BRIEF

published on 12/01/2025 at 15:05, 3 days 16 hours ago

Revelation Biosciences obtient le quorum pour sa prochaine réunion spéciale

Réunion Spéciale Soumission À La FDA Développement Futur Revelation Biosciences Formule Gémeaux
BRIEF

published on 12/01/2025 at 15:05, 3 days 16 hours ago

Revelation Biosciences Secures Quorum for Upcoming Special Meeting

Special Meeting Future Development FDA Submission Revelation Biosciences Gemini Formulation
PRESS RELEASE

published on 12/01/2025 at 15:00, 3 days 16 hours ago

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences, Inc. achieves quorum for Special Meeting on December 3, 2025, announces FDA meeting update & financial results. The company focuses on rebalancing inflammation using Gemini

Financial Results Special Meeting Inflammation FDA Meeting Revelation Biosciences
BRIEF

published on 11/20/2025 at 15:05, 14 days 16 hours ago

Revelation Biosciences Advances Toward FDA Meeting on Acute Kidney Injury Treatment

Clinical Trial Acute Kidney Injury FDA Meeting Gemini Revelation Biosciences
BRIEF

published on 11/20/2025 at 15:05, 14 days 16 hours ago

Revelation Biosciences progresse vers une réunion avec la FDA sur le traitement des lésions rénales aiguës

Essai Clinique Lésion Rénale Aiguë Réunion De La FDA Revelation Biosciences Gémeaux
PRESS RELEASE

published on 11/20/2025 at 15:00, 14 days 16 hours ago

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Revelation Biosciences announces FDA submission for Gemini as AKI treatment with positive PRIME study results. Company focuses on rebalancing inflammation

Inflammation FDA Submission Gemini Revelation Biosciences AKI Treatment
BRIEF

published on 11/06/2025 at 22:20, 28 days 9 hours ago

Revelation Biosciences annonce des résultats financiers améliorés

Résultats Financiers Étude Clinique Revelation Biosciences Formule Gémeaux Affections Inflammatoires
BRIEF

published on 11/06/2025 at 22:20, 28 days 9 hours ago

Revelation Biosciences Reports Improved Financial Results

Financial Results Clinical Study Revelation Biosciences Gemini Formulation Inflammatory Conditions
PRESS RELEASE

published on 11/06/2025 at 22:15, 28 days 9 hours ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Revelation Biosciences, Inc. reports financial results for Q3 2025 and highlights milestone achievements in clinical study and fundraising, focusing on rebalancing inflammation for health optimization

Financial Results Clinical Study Inflammation Revelation Biosciences Health Optimization
BRIEF

published on 10/29/2025 at 14:05, 1 month 6 days ago

Revelation Biosciences Reschedules Special Meeting Due to Technical Issues

Shareholders Special Meeting Reschedule Revelation Biosciences Technical Issue

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 54 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 24 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 19 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 24 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 24 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 33 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 9 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:14, 13 hours 10 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 24 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 24 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 39 minutes ago

Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 39 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE